Condition
Pancreatic Cancer Stage II
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Completed2
Unknown1
Not Yet Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06388967Recruiting
Pancreatic Cancer Detection Consortium
NCT06947382Completed
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
NCT06868693Not Yet Recruiting
Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer
NCT02043730Phase 2CompletedPrimary
Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.
NCT01065870Phase 2UnknownPrimary
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
Showing all 5 trials